Mouloudi E, Massa E, Georgiadou E, Iosifidis E, Katsika E, Rembelakos G, Gakis D, Imvrios G, Papanikolaou V, Papadopoulos S, Gritsi-Gerogianni N
Intensive Care Unit, "Hippokratio" University Hospital, Thessaloniki, Greece.
Transplant Proc. 2012 Nov;44(9):2721-3. doi: 10.1016/j.transproceed.2012.09.023.
The aim of this study was to evaluate infection complications as the reason for intensive care unit (ICU) admission among transplant recipients.
We studied all renal transplant recipients with infectious complications admitted to our ICU from 1992 to 2012:44.3% of all renal transplant recipients admitted to ICU. The epidemiology and prognosis of infectious complications requiring ICU admission were evaluated with analysis of mortality factors.
The 22 men and 5 women included in this study showed a mean age of 42.7 ± 12.3 years. The Acute Physiologic and Chronic Health Evaluation II and Seguential Organ Failure Assessment scores on ICU admission were 20 ± 4.6 and 8.6 ± 3.9, respectively. The main infections complications requiring ICU admission were cytomegalovirus pneumonia (n = 15) and aspergillus pneumonia (n = 4). Sixteen patients required hemodialysis and 14, catecholamine support upon ICU admission owing to septic shock. The mortality rate among study patients was 62.9%, versus 26.5% for noninfectious renal transplant recipients requiring ICU admissions. Catecholamine support at ICU admission was independently related to mortality.
The mortality rate of renal transplant recipients admitted to ICU owing infection complications was higher than that of noninfected renal transplant patients. These data suggest that infections and septic shock in renal transplant recipients requiring ICU admission worsen their outcome significantly.
本研究旨在评估感染并发症作为移植受者入住重症监护病房(ICU)的原因。
我们研究了1992年至2012年入住我院ICU的所有有感染并发症的肾移植受者:占所有入住ICU的肾移植受者的44.3%。通过对死亡因素的分析评估了需要入住ICU的感染并发症的流行病学和预后。
本研究纳入的22名男性和5名女性的平均年龄为42.7±12.3岁。入住ICU时的急性生理与慢性健康状况评分II和序贯器官衰竭评估评分分别为20±4.6和8.6±3.9。需要入住ICU的主要感染并发症是巨细胞病毒肺炎(n = 15)和曲霉肺炎(n = 4)。16例患者需要血液透析,14例因感染性休克在入住ICU时需要儿茶酚胺支持。研究患者的死亡率为62.9%,而因非感染性原因入住ICU的肾移植受者的死亡率为26.5%。入住ICU时的儿茶酚胺支持与死亡率独立相关。
因感染并发症入住ICU的肾移植受者的死亡率高于未感染的肾移植患者。这些数据表明,需要入住ICU的肾移植受者的感染和感染性休克显著恶化了他们的预后。